Nurix Therapeutics (NRIX) Stock Overview
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NRIX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Nurix Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.63 |
| 52 Week High | US$29.56 |
| 52 Week Low | US$8.18 |
| Beta | 2.34 |
| 1 Month Change | 26.10% |
| 3 Month Change | -7.81% |
| 1 Year Change | -57.10% |
| 3 Year Change | -11.93% |
| 5 Year Change | -59.58% |
| Change since IPO | -44.08% |
Recent News & Updates
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Oct 12
Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones
Oct 11Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price
Sep 30Recent updates
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Oct 12Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones
Oct 11Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price
Sep 30Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Aug 18Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Jul 14Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being
May 12Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
Apr 17Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Apr 17Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Mar 22Nurix Therapeutics: A Story To Monitor
Feb 18Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Jan 30Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me
Jan 05Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%
Nov 07Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth
Oct 31Nurix: An Attractive Early-Stage Biotech Play
Oct 08Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Sep 07Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data
Sep 04Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans
Jul 15Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Shareholder Returns
| NRIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | 3.0% | 1.1% |
| 1Y | -57.1% | 2.7% | 16.7% |
Return vs Industry: NRIX underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: NRIX underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| NRIX volatility | |
|---|---|
| NRIX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NRIX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 286 | Arthur Sands | www.nurixtx.com |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Nurix Therapeutics, Inc. Fundamentals Summary
| NRIX fundamental statistics | |
|---|---|
| Market cap | US$801.13m |
| Earnings (TTM) | -US$244.78m |
| Revenue (TTM) | US$83.69m |
Is NRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRIX income statement (TTM) | |
|---|---|
| Revenue | US$83.69m |
| Cost of Revenue | US$301.10m |
| Gross Profit | -US$217.42m |
| Other Expenses | US$27.37m |
| Earnings | -US$244.78m |
Last Reported Earnings
Aug 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | -259.80% |
| Net Profit Margin | -292.50% |
| Debt/Equity Ratio | 0% |
How did NRIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 22:58 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2024/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nurix Therapeutics, Inc. is covered by 24 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| Peter Lawson | Barclays |